Latest Blueprint Medicines Stories
SAN FRANCISCO, Dec.
- Builds on Company's novel discovery of several kinase fusion genes in cancer - CAMBRIDGE, Mass., Nov.
-Proceeds to support continued advancement of highly selective kinase inhibitors to genomically defined cancers, including first-in-class FGFR4 and KIT Exon 17 inhibitors- CAMBRIDGE, Mass.,
--Genomic Data in Study Published in Nature Communications Suggests New Treatment Strategies for These Hard to Treat Women's Reproductive Cancers-- BALTIMORE and CAMBRIDGE, Mass., Sept.
- Findings and research approach published in Nature Communications - CAMBRIDGE, Mass., Sept.
- In vivo data support potential clinical benefit of first therapeutic to target a defined subset of liver cancer patients based on genetic profile - CAMBRIDGE, Mass., Sept.
CAMBRIDGE, Mass., July 24, 2014 /PRNewswire/ -- Blueprint Medicines (Blueprint), a leader in discovering highly selective kinase inhibitors for genomically defined cancer patients, today announced
- To swell, as grain or wood with water.